Merck has made the decision to end 2 clinical trials evaluating its programmed death receptor-1 (PD-1)-blocking antibody, Keytruda ® (pembrolizumab).

Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no contraindications.

Greater ability to function normally, greater reduction in activity limitations, and greater rate of satisfaction seen with medication ...

(HealthDay News) — Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study published online Aug. 23 in Alzheimer’s & Dementia.

(HealthDay News) — Counties with high pharmacy desert densities also face social vulnerability and health care provider shortages, according to a research letter published online Aug. 23 in JAMA ...

Plexiform neurofibromas are tumors that grow in an infiltrative pattern along the peripheral nerve sheath, resulting in pain and functional impairment in patients with NF1.